Mundo2 schreef:
[quote=patrick 22]
AEK Research upgrades Pharming to Outperformer
The European Medicines Authority (EMA) is expected to provide an opinion on
Pharming's lead product Rhucin, this week (21-24 June). AEK Research expects the
EMA to provide a positive opinion on the use of Rhucin in treating acute attacks
of Hereditary Angioedema (HAE). After approval, our discounted cash flow
analysis indicates a fair value of Pharming of Eur 0.50 per share. AEK Research
raises its recommendation on Pharming to Outperformer (from Market performer).
[/quote]
zullen ze al voorkennis hebben of doen ze gewoon een gokje